Document Detail


Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.
MedLine Citation:
PMID:  16802358     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the incidence and extent of coronary artery calcification (CAC) as measured by electron beam computed tomography (EBCT) in patients with systemic lupus erythematosus (SLE) and controls, and to identify variables associated with CAC in patients with SLE. METHODS: Female patients with SLE and matched controls were recruited; EBCT of the coronary arteries was performed, and laboratory values (including the homocysteine concentration, the lipid level, the high-sensitivity C-reactive protein [hsCRP] concentration, the glomerular filtration rate [GFR], and the level of soluble CD154 [sCD154]) were determined. For patients, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index and the SLE Disease Activity Index scores were recorded. Tests of association between the CAC score and the above-mentioned variables were performed. RESULTS: The incidence of CAC was higher in patients with SLE than in controls (P = 0.009), and patients had a higher mean raw CAC (rCAC) score (87.9 versus 9.6 in controls; P = 0.02). In particular, more CAC-positive patients than CAC-positive controls had rCAC scores above the 75th percentile (P = 0.003). Among both patients and controls, those with CAC were approximately 10 years older than those without CAC. In addition to age, a significant determinant of positive CAC status in both groups was the number of cardiovascular risk factors. In patients with SLE, CAC was associated with a higher homocysteine concentration, a lower GFR, and longer disease duration. In controls, the total cholesterol level correlated positively with CAC. When multivariate logistic regression methods were applied to candidate explanatory variables, homocysteine concentration, age, and disease duration (but not the levels of sCD154 or hsCRP) contributed significantly to CAC status. The methylenetetrahydrofolate reductase C677T genotype was not a predictor of hyperhomocysteinemia or CAC status. CONCLUSION: Among patients with SLE, the homocysteine concentration, the GFR, age, and disease duration were associated with CAC. CAC occurred more frequently and was more extensive in patients with SLE than in controls, suggesting that EBCT could be used to detect premature atherosclerosis in the former group. An elevated homocysteine concentration might identify patients with SLE who are likely to have premature atherosclerosis and who would benefit from evaluation of CAC by EBCT.
Authors:
Joan M Von Feldt; Lisabeth V Scalzi; Andrew J Cucchiara; Suneetha Morthala; Carmel Kealey; Stephanie D Flagg; Anna Genin; Alison L Van Dyke; Eleni Nackos; Avantika Chander; Erika Gehrie; Randy Q Cron; Alexander S Whitehead
Related Documents :
7189028 - Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis.
19796558 - An evaluation of the efficacy of the toe brachial index measuring vascular involvement ...
2785628 - Outcome in systemic lupus erythematosus: a prospective study of patients from a defined...
15498048 - Interleukin (il)-10, il-1ra and il-12 profiles in active and quiescent systemic lupus e...
22356568 - Inflammatory cytokines at admission-independent prognostic markers in patients with acu...
19787418 - Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for m...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  54     ISSN:  0004-3591     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-08-18     Completed Date:  2006-09-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2220-7     Citation Subset:  AIM; IM    
Affiliation:
University of Pennsylvania, 5 Maloney, Suite 504, 3600 Spruce Street, Philadelphia, PA 19104, USA. vonfeldt@mail.med.upenn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Adult
Calcinosis / diagnosis,  etiology,  pathology*
Case-Control Studies
Coronary Angiography
Coronary Artery Disease / diagnosis,  etiology,  pathology*
Female
Glomerular Filtration Rate
Homocysteine / blood*
Humans
Lupus Erythematosus, Systemic / blood*,  complications,  drug therapy,  pathology*
Methylenetetrahydrofolate Reductase (NADPH2) / genetics
Middle Aged
Polymorphism, Genetic
Predictive Value of Tests
Regression Analysis
Severity of Illness Index
Tomography, X-Ray Computed / methods
Grant Support
ID/Acronym/Agency:
M01-RR-00040/RR/NCRR NIH HHS; R01-AR-048257/AR/NIAMS NIH HHS; R01-AR-47663/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 454-28-4/Homocysteine; EC 1.5.1.20/Methylenetetrahydrofolate Reductase (NADPH2)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus.
Next Document:  Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in a...